Omalizumab responders in the present study population were found to have a significantly higher baseline UCT score than omalizumab non-responders, which pointed out to milder disease activity and was also reported by Salman et al.13Presence of angioedema,14 female gender,15 high CRP levels,16 ASST positivity,17 eosinopenia and basopenia 18 has been reported to be associated with poor response to omalizumab. The gene discussed is CRP; the disease is angioedema.